Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Berlin - Delayed Quote EUR

Ascletis Pharma Inc (2VJ.BE)

Compare
0.8200
+0.0500
+(6.49%)
As of 4:30:05 PM GMT+1. Market Open.
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
56,596
56,596
54,090
76,876
35,001
Cost of Revenue
30,606
30,606
78,782
37,703
58,498
Gross Profit
25,990
25,990
-24,692
39,173
-23,497
Operating Expense
326,198
326,198
314,937
223,256
129,439
Operating Income
-300,208
-300,208
-339,629
-184,083
-152,936
Net Non Operating Interest Income Expense
99,134
99,134
44,005
22,381
40,491
Pretax Income
-144,715
-144,715
-314,843
-199,017
-209,241
Net Income Common Stockholders
-144,715
-144,715
-314,843
-199,017
-209,241
Diluted NI Available to Com Stockholders
-144,715
-144,715
-314,843
-199,017
-209,241
Basic EPS
-0.13
-0.13
-0.29
-0.18
-0.20
Diluted EPS
-0.13
-0.13
-0.29
-0.18
-0.20
Basic Average Shares
1,074,103.4600
1,074,103.4600
1,087,029.8900
1,097,608.0540
1,040,055.7310
Diluted Average Shares
1,074,103.4600
1,074,103.4600
1,087,029.8900
1,097,608.0540
1,040,055.7310
Rent Expense Supplemental
14,193
14,193
11,227
12,048
15,217
Total Expenses
356,804
356,804
393,719
260,959
187,937
Net Income from Continuing & Discontinued Operation
-144,715
-144,715
-314,843
-199,017
-209,241
Normalized Income
-213,689
-213,689
-262,974
-201,501
-156,564
Interest Income
99,278
99,278
44,162
22,506
40,626
Interest Expense
144
144
157
125
135
Net Interest Income
99,134
99,134
44,005
22,381
40,491
EBIT
-144,571
-144,571
-314,686
-198,892
-209,106
EBITDA
-126,091
-126,091
-284,495
-169,347
-181,943
Reconciled Cost of Revenue
30,606
30,606
78,782
37,703
58,498
Reconciled Depreciation
18,480
18,480
30,191
29,545
27,163
Net Income from Continuing Operation Net Minority Interest
-144,715
-144,715
-314,843
-199,017
-209,241
Total Unusual Items Excluding Goodwill
68,974
68,974
-51,869
2,484
-52,677
Total Unusual Items
68,974
68,974
-51,869
2,484
-52,677
Normalized EBITDA
-195,065
-195,065
-232,626
-171,831
-129,266
12/31/2020 - 8/13/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KK3A.DU Cytokinetics Inc
44.80
+1.82%
 
1VT.BE Viking Therapeutics Inc
27.46
+0.70%
 
EWTX Edgewise Therapeutics, Inc.
25.78
+2.79%
 
ATNM Actinium Pharmaceuticals, Inc.
1.1550
+0.43%
 
BMEA Biomea Fusion, Inc.
2.9200
+2.82%
 
AKRO Akero Therapeutics, Inc.
48.83
+2.85%
 
CYTK Cytokinetics, Incorporated
47.53
+1.89%
 
ALT Altimmune, Inc.
6.05
+2.28%